E. M. Petrova
E. M. Petrova has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Marina V. Karlina
Research-and-manufacturing company “HOME OF PHARMACY
3 shared publications - Vera Mikhaylovna Kosman
Research-and-manufacturing company “HOME OF PHARMACY
3 shared publications - Marina Nikolayevna Makarova
Research and Manufacturing Company “HOME OF PHARMACY
2 shared publications - Valeriy Gennadievich Makarov
Research and Manufacturing Company “HOME OF PHARMACY
2 shared publications - A. A. Matichina
RMC «HOME OF PHARMACY
1 shared publication - A. L. Vladykin
JSC “Valenta Pharm
1 shared publication
Latest Publications
- Open Access
- 18 December 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (4) , 426-439
Ketoprofen Comparative Pharmacokinetics Analysis in Humans and Animals: A Review
INTRODUCTION . Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) with pronounced analgesic, anti-inflammatory and antipyretic effect. Ketoprofen pharmacokinetics is comparatively well described in various in vivo models. Since it is potentially possible to create new dosage forms of ketoprofen, with pharmacokinetics studies contributing to high-quality pharmaceutical development, a comparative assessment is relevant for the data on animals and humans. AIM. This study aimed to identify animal species relevant for preclinical studies of different ketoprofen dosage forms by summarising bioanalytical methods used to assess pharmacokinetics and by comparing various test systems. DISCUSSION . Reversed-phase high-performance liquid chromatography with ultraviolet/mass spectrometric detection and acetonitrile or methanol-based eluents in various buffer solutions is the most ubiquitous method for ketoprofen analysis in biomaterials. Ketoprofen pharmacokinetics was studied in humans and animals of several phylogenetic species using various dosage forms (injectable solutions, tablets, paste forms, etc.) and the relevant administration (intravenous, intramuscular, oral, transdermal). High drug bioavailability was noted for different routes. Maximum concentration (C max ) range at similar doses and similar time parameters (time to maximum concentration, T max , half-life, T 1/2 and mean residence time, MRT) for the three main administration routes (oral, intravenous and intramuscular) was comparable in humans and rats, cats, and dogs; thus these test systems were suggested for pharmacokinetics studies of ketoprofen preparations. CONCLUSIONS . The analysis suggested that rats and larger animals (cats, dogs) can serve as test systems in ketoprofen pharmacokinetics studies, at least for oral, intravenous, and intramuscular administration. Using ketoprofen as an example, the study showed feasibility of integrating heterogeneous pharmacokinetic data, as well as comparison challenges due to variable test systems, study objects, dosages, and administration routes.
- 18 December 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (4) , 426-439
Open AccessKetoprofen Comparative Pharmacokinetics Analysis in Humans and Animals: A Review
INTRODUCTION . Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) with pronounced analgesic, anti-inflammatory and antipyretic effect. Ketoprofen pharmacokinetics is comparatively well described in various in vivo models. Since it is potentially possible to create new dosage forms of ketoprofen, with pharmacokinetics studies contributing to high-quality pharmaceutical development, a comparative assessment is relevant for the data on animals and humans. AIM. This study aimed to identify animal species relevant for preclinical studies of different ketoprofen dosage forms by summarising bioanalytical methods used to assess pharmacokinetics and by comparing various test systems. DISCUSSION . Reversed-phase high-performance liquid chromatography with ultraviolet/mass spectrometric detection and acetonitrile or methanol-based eluents in various buffer solutions is the most ubiquitous method for ketoprofen analysis in biomaterials. Ketoprofen pharmacokinetics was studied in humans and animals of several phylogenetic species using various dosage forms (injectable solutions, tablets, paste forms, etc.) and the relevant administration (intravenous, intramuscular, oral, transdermal). High drug bioavailability was noted for different routes. Maximum concentration (C max ) range at similar doses and similar time parameters (time to maximum concentration, T max , half-life, T 1/2 and mean residence time, MRT) for the three main administration routes (oral, intravenous and intramuscular) was comparable in humans and rats, cats, and dogs; thus these test systems were suggested for pharmacokinetics studies of ketoprofen preparations. CONCLUSIONS . The analysis suggested that rats and larger animals (cats, dogs) can serve as test systems in ketoprofen pharmacokinetics studies, at least for oral, intravenous, and intramuscular administration. Using ketoprofen as an example, the study showed feasibility of integrating heterogeneous pharmacokinetic data, as well as comparison challenges due to variable test systems, study objects, dosages, and administration routes.
- Open Access
- 19 April 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (11-12) , 41-48
Study of the Safety and Toxicokinetic Parameters of the Drug Eladis® in Preclinical Trials with Repeated Administration
Cough is one of the most common reasons for initial visits to healthcare providers, affecting 40–50% of patients with viral respiratory tract infections. Treatment options for cough include medications that block signal transmission at the central or peripheral level of the reflex arc, as well as mucolytic and expectorant agents. Valenta Pharm JSC has developed an innovative drug, Eladis® (film-coated tablets, 20 mg and 40 mg), intended for the treatment of cough in patients with acute respiratory infections. The aim of the present study was to assess the safety profile and toxicokinetic parameters of the drug after repeated administrations. In the study conducted on mature rabbits, the drug was administered orally at doses of 1, 3, or 6 tablets/animal over 28 days, corresponding to 13.3, 40, and 80 mg/kg, respectively. No signs of intoxication were observed in any of the experimental groups. To evaluate toxicokinetic parameters, blood samples were collected from the marginal ear vein after the 1st and 28th days of administration. Both single and multiple (28-day) administrations of the drug showed a statistically significant increase in Cmax and AUC0–24 with increasing doses. No drug accumulation was observed following repeated administration on day 28. In a separate study on juvenile rats, Eladis® was administered intragastrically for 30 days at doses of 11.8, 118, and 236 mg/kg. The results indicated no significant effects of the drug on body weight gain, animal behavior in a battery of functional tests, as well as the estimated physiological, biochemical, and hematological parameters. The drug demonstrated no local irritant or immunotoxic effects and had no impact on spermatogenesis.
- 19 April 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (11-12) , 41-48
Open AccessStudy of the Safety and Toxicokinetic Parameters of the Drug Eladis® in Preclinical Trials with Repeated Administration
Cough is one of the most common reasons for initial visits to healthcare providers, affecting 40–50% of patients with viral respiratory tract infections. Treatment options for cough include medications that block signal transmission at the central or peripheral level of the reflex arc, as well as mucolytic and expectorant agents. Valenta Pharm JSC has developed an innovative drug, Eladis® (film-coated tablets, 20 mg and 40 mg), intended for the treatment of cough in patients with acute respiratory infections. The aim of the present study was to assess the safety profile and toxicokinetic parameters of the drug after repeated administrations. In the study conducted on mature rabbits, the drug was administered orally at doses of 1, 3, or 6 tablets/animal over 28 days, corresponding to 13.3, 40, and 80 mg/kg, respectively. No signs of intoxication were observed in any of the experimental groups. To evaluate toxicokinetic parameters, blood samples were collected from the marginal ear vein after the 1st and 28th days of administration. Both single and multiple (28-day) administrations of the drug showed a statistically significant increase in Cmax and AUC0–24 with increasing doses. No drug accumulation was observed following repeated administration on day 28. In a separate study on juvenile rats, Eladis® was administered intragastrically for 30 days at doses of 11.8, 118, and 236 mg/kg. The results indicated no significant effects of the drug on body weight gain, animal behavior in a battery of functional tests, as well as the estimated physiological, biochemical, and hematological parameters. The drug demonstrated no local irritant or immunotoxic effects and had no impact on spermatogenesis.
- Open Access
- 1 September 2024
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 11 (4) , 351-363
On the assessment of contamination and analysis of control samples in toxicokinetics studies
Relevance. The evaluation of control samples contamination is a necessary element for confirming the correctness of toxicokinetic studies (TK), concomitant with the study of toxicity of drugs and products. At the same time, insufficient elaboration of existing regulatory documents necessitates discussion of practical aspects and improvement of the regulatory framework. Purpose. The work is devoted to the consideration of experimental experience of control samples contamination in TK studies. Materials and methods. As experimental examples, two studies of TK drugs performed using rabbits with oral administration of study drugs for 28 (Study 1) or 90 (Study 2) days were considered. Results. Study 1 revealed a contamination level of 17–25 % (on the first and last days of study drug administration, respectively). Contamination of bioassays can occur in vivo (contamination of animals) and ex vivo (at the stage of bioassay sampling, at the pre-analytical stage and analytical stage). The nature of the analyte detection in the samples made it possible to exclude contamination in vivo, and the results of an internal investigation suggested that it occurred at the stage of biosample selection. In Study 2, a number of preventive measures were implemented and a slight level of contamination was obtained (0.83 %), which did not affect the completeness and correctness of results interpretation. Conclusion. Based on experimental experience, recommendations for minimizing and preventing contamination of control samples during the biological part, pre-analytical and analytical stages of studies were formulated. Presumably, in the presence of a random nature of contamination indicating its ex vivo origin, the level of contamination not exceeding 25 % can be considered insignificant, i.e. not leading to further deviation and cancellation of the results of the entire study
- 1 September 2024
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 11 (4) , 351-363
Open AccessOn the assessment of contamination and analysis of control samples in toxicokinetics studies
Relevance. The evaluation of control samples contamination is a necessary element for confirming the correctness of toxicokinetic studies (TK), concomitant with the study of toxicity of drugs and products. At the same time, insufficient elaboration of existing regulatory documents necessitates discussion of practical aspects and improvement of the regulatory framework. Purpose. The work is devoted to the consideration of experimental experience of control samples contamination in TK studies. Materials and methods. As experimental examples, two studies of TK drugs performed using rabbits with oral administration of study drugs for 28 (Study 1) or 90 (Study 2) days were considered. Results. Study 1 revealed a contamination level of 17–25 % (on the first and last days of study drug administration, respectively). Contamination of bioassays can occur in vivo (contamination of animals) and ex vivo (at the stage of bioassay sampling, at the pre-analytical stage and analytical stage). The nature of the analyte detection in the samples made it possible to exclude contamination in vivo, and the results of an internal investigation suggested that it occurred at the stage of biosample selection. In Study 2, a number of preventive measures were implemented and a slight level of contamination was obtained (0.83 %), which did not affect the completeness and correctness of results interpretation. Conclusion. Based on experimental experience, recommendations for minimizing and preventing contamination of control samples during the biological part, pre-analytical and analytical stages of studies were formulated. Presumably, in the presence of a random nature of contamination indicating its ex vivo origin, the level of contamination not exceeding 25 % can be considered insignificant, i.e. not leading to further deviation and cancellation of the results of the entire study